← Back to Search

Unknown

CT-868 for Obesity

Phase 2

Waitlist Available

Research Sponsored by Carmot Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline up to 12 and 26 weeks

Awards & highlights

Study Summary

This trial will test a new drug to see if it can lower HbA1c in overweight and obese people with type 2 diabetes.

Eligible Conditions

Obesity
Type 2 Diabetes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline up to 12 and 26 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline up to 12 and 26 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline up to 12 and 26 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in hemoglobin A1c (HbA1c)

Secondary outcome measures

Change in mean body weight

Fasting plasma glucose

Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: CT-868 Maximum Tolerated DoseExperimental Treatment1 Intervention

CT-868

Group II: CT-868 Low DoseExperimental Treatment1 Intervention

CT-868

Group III: PlaceboPlacebo Group1 Intervention

Placebo

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Carmot Therapeutics, Inc.Lead Sponsor

5 Previous Clinical Trials

366 Total Patients Enrolled

Michael ElliottStudy DirectorCarmot Therapeutics, Inc.

5 Previous Clinical Trials

366 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I a suitable candidate to participate in this experiment?

"In order to be considered for this trial, individuals must have a diagnosis of obesity and fall within the age range between 18 to 75 years old. Approximately 96 participants are being sought after."

Answered by AI

What deleterious effects may CT-868 have on individuals?

"Our safety assessment of CT-868 is a moderate 2 due to the presence of data indicating its relative safety but no proof yet that it can be effective."

Answered by AI

Does this research protocol accommodate participants aged 70 or older?

"To be part of this trial, participants must have attained the age of majority and yet to reach their seventieth year. There are 402 trials for minors and 1690 studies catered towards elderly persons."

Answered by AI

Are additional participants being sought for this research?

"Clinicaltrials.gov data indicates that this trial is not currently seeking new enrollees, despite having been posted on February 22nd 2022 and last edited July 24th of the same year. Fortunately, there are over two thousand four hundred twenty-three other clinical trials actively enrolling patients right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

2022. "A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05110846.